Clinical trial · Observational
Immune Profiles in Myasthenia Gravis
Comparison of Lymphocyte Subset, Cytokine and Complement Profiles in Myasthenia Gravis of Different Severity, Disease Time-points, and Treatment History
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aim to better describe the immune profile in myasthenia gravis (MG), including lymphocyte subset, cytokine and complement profiles; how they differ between patients of different severity, at times of disease exacerbation, and with different immunosuppressive treatments. The investigators hope to build a clearer picture of how different immune measures vary in MG, contributing to the understanding of the patho\[physiology of the disease, and working towards a biomarker that might help clinicians optimise an individual's treatment. the investigators aim to take into account the heterogeneity of MG by taking into account age of onset of MG (early vs late onset) and focussing on acetylcholine receptor antibody (AChR) positive, non-thymomatous MG aged 18-80.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (4)
- label
- Stable Immunosuppressed
- description
- Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on prednsiolone \<5mg/day and azathioprine or mycophenolate.
- label
- Stable Non-immunosuppressed
- description
- Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on ≤120mg pyridostigmine/day and no immunosuppression.
- label
- Refractory
- description
- Acetylcholine repector antibody positvie myasthenia gravis, meeting the NHS England criteria for Rituximab
- label
- Healthy Controls
- description
- No autoimmune disease or current solid organ or haematological malignancy.
Primary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * All participants: * Are able to give valid written consent * are aged between the ages of 18 and 80 Stable Immunosuppressed * Have a diagnosis of AChR positive myasthenia gravis (can be ocular, bulbar or generalised) * MGFA Post-intervention Status MM or better with no clinical relapse for 2 years * On either azathioprine or MMF along with ≤5mg/day of prednisolone * No prednisolone dose increase or decrease in past 12 months * No increase in azathioprine or MMF dose for 2 years (allowing for cessation for up to 1 month) Stable Non-Immunosuppressed * have a diagnosis of AChR positive myasthenia gravis (can be ocular, bulbar or generalised) * MGFA Post-intervention Status MM or better on only low-dose cholinesterase inhibitors (≤\<120 mg pyridostigmine/day) for over two years and ≤5mg/day of prednisolone for over two years. * No prednisolone dose increase or decrease in past 12 months Refractory * have a diagnosis of AChR positive myasthenia gravis (can be ocular, bulbar or generalised) * have been deemed eligible to be refractory to standard treatment and eligible for rituximab as per the NHS England criteria. Exclusion Criteria for all participants: * Are unable to give valid consent * Co-existing autoimmune condition for which azathioprine or mycophenolate mofetil are treatments (e.g. inflammatory bowel disease, rheumatoid arthritis, neuromyotonia) * Currently undergoing treatment for solid organ or haematological malignancy, or previous thymoma * Clinical frailty scale ≥6
References
Publications (0)
Data not yet available